Direct-acting antiviral agent–based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study

MLA

Jérôme Dumortier, et al. “Direct-Acting Antiviral Agent–based Regimen for HCV Recurrence after Combined Liver-Kidney Transplantation: Results from the ANRS CO23 CUPILT Study.” American Journal of Transplantation, vol. 17, Nov. 2017, pp. 2869–78. EBSCOhost, https://doi.org/10.1111/ajt.14490.

APA

Jérôme Dumortier, A. Rohel, Jean-Charles Duclos-Vallée, Christophe Duvoux, Vincent Di Martino, Christine Silvain, Sébastien Dharancy, Danielle Botta-Fridlund, Sylvie Radenne, Maryline Debette-Gratien, Nassim Kamar, Audrey Coilly, Vincent Leroy, Georges-Philippe Pageaux, Armand Abergel, Louis d’Alteroche, Emilie Rossignol, Claire Francoz, Pauline Houssel-Debry, … Victor de Lédinghen. (2017). Direct-acting antiviral agent–based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study. American Journal of Transplantation, 17, 2869–2878. https://doi.org/10.1111/ajt.14490

Chicago

Jérôme Dumortier, A. Rohel, Jean-Charles Duclos-Vallée, Christophe Duvoux, Vincent Di Martino, Christine Silvain, Sébastien Dharancy, et al. 2017. “Direct-Acting Antiviral Agent–based Regimen for HCV Recurrence after Combined Liver-Kidney Transplantation: Results from the ANRS CO23 CUPILT Study.” American Journal of Transplantation 17 (November): 2869–78. doi:10.1111/ajt.14490.